Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 132, Issue 4, Pages 978-987
Publisher
Wiley
Online
2012-07-23
DOI
10.1002/ijc.27732
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions
- (2012) Kevin J. Curran et al. JOURNAL OF GENE MEDICINE
- Cancer immunotherapy
- (2012) Thomas F. Gajewski Molecular Oncology
- A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia
- (2011) John Schindler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
- (2011) D. J. FitzGerald et al. CANCER RESEARCH
- A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer
- (2011) John E. Weldon et al. FEBS Journal
- Cancer Immunotherapy Comes of Age
- (2011) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia
- (2011) Robert J. Kreitman et al. LEUKEMIA & LYMPHOMA
- Synergistic Anticancer Effects of the 9.2.27PE Immunotoxin and ABT-737 in Melanoma
- (2011) Karianne Risberg et al. PLoS One
- ABT-737 Overcomes Resistance to Immunotoxin-Mediated Apoptosis and Enhances the Delivery of Pseudomonas Exotoxin-Based Proteins to the Cell Cytosol
- (2010) R. Traini et al. MOLECULAR CANCER THERAPEUTICS
- Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
- (2010) S. K. Tahir et al. MOLECULAR CANCER THERAPEUTICS
- Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression
- (2009) Christian Bogner et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
- (2009) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer
- (2008) C. L. Hann et al. CANCER RESEARCH
- Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
- (2008) A. R. Shoemaker et al. CLINICAL CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started